Pediatric steroid-resistant nephrotic syndrome

Current Problems in Pediatric and Adolescent Health Care

Volumn 31, Issue 9, 1999, Pages 280-307

  McBryde, Kevin D ^a   Kershaw, David B ^a   Smoyer, William E ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANGIOTENSIN CONVERTING ENZYME INHIBITORS; ANTI INFLAMMATORY AGENTS, NON STEROIDAL; ANTILIPEMIC AGENT; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; IMMUNOSUPPRESSIVE AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; STEROID; ALPHA TOCOPHEROL; AZATHIOPRINE; CHLORAMBUCIL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DICLOFENAC; FLURBIPROFEN; FUROSEMIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUPROFEN; INDOMETACIN; LEVAMISOLE; LOOP DIURETIC AGENT; MECLOFENAMIC ACID; MERCAPTOPURINE; METHYLPREDNISOLONE; METOLAZONE; MIZORIBINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PEFLOXACIN; PREDNISONE; THIAZIDE DIURETIC AGENT; TSUKUBAENOLIDE; UNINDEXED DRUG; VINCRISTINE;

CHILD; DRUG COMBINATION; DRUG RESISTANCE; GENETICS; HUMAN; HYPERLIPIDEMIA; NEPHROTIC SYNDROME; PATHOPHYSIOLOGY; REVIEW; UNITED STATES; ARTICLE; CHILDHOOD DISEASE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE CLASSIFICATION; DRUG EFFICACY; FEMALE; FOCAL GLOMERULOSCLEROSIS; GASTROINTESTINAL SYMPTOM; GINGIVA HYPERPLASIA; HEADACHE; HISTOPATHOLOGY; HYPERTENSION; HYPOALBUMINEMIA; IMMUNOADSORPTION; INFECTION COMPLICATION; KIDNEY FAILURE; LABORATORY DIAGNOSIS; LEUKOPENIA; MALE; PLASMAPHERESIS; RISK FACTOR; THROMBOEMBOLISM; URINALYSIS;

ALKYLATING AGENTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTILIPEMIC AGENTS; CHILD; CYCLOSPORINE; DIURETICS; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; HUMAN; HYPERLIPIDEMIA; IMMUNOSUPPRESSIVE AGENTS; NEPHROTIC SYNDROME; STEROIDS; UNITED STATES;

EID: 0035569027     PISSN: 15385442     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (165)

1. Cameron JS. The nephrotic syndrome: a historical review. In: Cameron JS, Glassock RJ, Whelton A, editors. The nephrotic syndrome. Volume 8. New York: Marcel Dekker, Inc; 1988. p. 3-56.
2. Arneil GC, Lam CN. Long-term assessment of steroid therapy in childhood nephrosis. Lancet 1966;2:819-21.
3. Clark AG, Barratt TM. Steroid-responsive nephrotic syndrome. In: Barratt TM, Avner ED, Harmon WE, editors. Pediatric nephrology. 4th ed. Baltimore: Lippincott Williams & Wilkins; 1998. p. 731-47.
4. The International Study of Kidney Disease in Children. Primary nephrotic syndrome in children: clinical significance of histopathologic variants of minimal change and of diffuse mesangial hypercellularity. Kidney Int 1981;20:765-71.
5. Niaudet P, Gagnadoux MF, Broyer M. Treatment of childhood steroid-resistant idiopathic nephrotic syndrome. Adv Nephrol Necker Hosp 1998;28:43-61.
6. The International Study of Kidney Disease in Children. The primary nephrotic syndrome in children: identification of patients with minimal change nephrotic syndrome from initial response to prednisone. J Pediatr 1981;98:561-4.
7. Nash MA, Edelmann CM Jr, Bernstein J, Barnett HL. The nephrotic syndrome. In: Edelman CM Jr, editor. Pediatric kidney disease. 2nd ed. Boston: Little, Brown, and Company; 1992. p. 1247-66.
8. Srivastava T, Simon SD, Alon US. High incidence of focal segmental glomerulosclerosis in nephrotic syndrome of childhood. Pediatr Nephrol 1999;13:13-8.
9. Hogg RJ, Portman RJ, Milliner D, Lemley KV, Eddy A, Ingelfinger J. Evaluation and management of proteinuria and nephrotic syndrome in children: recommendations from a pediatric nephrology panel established at the National Kidney Foundation Conference on Proteinuria, Albuminuria, Risk, Assessment, Detection, and Elimination (PARADE). Pediatrics 2000;105:1242-9.
10. The International Study of Kidney Disease in Children. Nephrotic syndrome in children: prediction of histopathology from clinical and laboratory characteristics at time of diagnosis. Kidney Int 1978;13:159-65.
11. Sorof JM, Hawkins EP, Brewer ED, Boydstun II, Kale AS, Powell DR. Age and ethnicity affect the risk and outcome of focal segmental glomerulosclerosis. Pediatr Nephrol 1998; 12:764-8.
12. Bonila-Felix M, Parra C, Dajani T, Ferris M, Swinford RD, Portman RJ, et al. Changing patterns in the histopathology of idiopathic nephrotic syndrome in children. Kidney Int 1999; 55:1885-90.
13. The Southwest Pediatric Nephrology Study Group. Focal segmental glomerulosclerosis in children with idiopathic nephrotic syndrome: a report of the Southwest Pediatric Nephrology Study Group. Kidney Int 1985;27:442-9.
14. Niaudet P. Steroid-resistant idiopathic nephrotic syndrome. In: Barratt TM, Avner ED, Harmon WE, editors. Pediatric nephrology. 4th ed. Baltimore: Lippincott Williams & Wilkins; 1998. p. 749-63.
15. Taylor GM, Neuhaus TJ, Shah V, Dillon S, Barratt TM. Charge and size selectivity of proteinuria in children with idiopathic nephrotic syndrome. Pediatr Nephrol 1997;11:404-10.
16. The Southwest Pediatric Nephrology Study Group. Childhood nephrotic syndrome associated with diffuse mesangial hyper-cellularity: a report of the Southwest Pediatric Nephrology Study Group. Kidney Int 1983;23:87-94.
17. Kher KK, Sweet M, Makker SP. Nephrotic syndrome in children. Curr Probl Pediatr 1988;18:197-251.
18. Kaysen GA. Nonrenal complications of the nephrotic syndrome. Annu Rev Med 1994;45:201-10.
19. Harris RC, Ismail N. Extrarenal complications of the nephrotic syndrome. Am J Kidney Dis 1994;23:477-97.
20. Orth SR, Ritz E. The nephrotic syndrome. N Engl J Med 1998;338:1202-11.
21. Candiano G, Musante L, Carraro M, Faccini L, Campanacci L, Zennaro C, et al. Apolipoproteins prevent glomerular albumin permeability induced in vitro by serum from patients with focal segmental glomerulosclerosis. J Am Soc Nephrol 2001;12:143-50.
22. White RHR, Glasgow EF. Clinicopathological study of nephrotic syndrome in childhood. Lancet 1970;I:1353-9.
23. Taylor GM, Neuhaus TJ, Shah V, Dillon S, Barratt TM. Charge and size selectivity of proteinuria in children with idiopathic nephrotic syndrome. Pediatr Nephrol 1997; 11:404-10.
24. Olson JL, Schwartz MM. The nephrotic syndrome: minimal change disease, focal segmental glomerulosclerosis, and miscellaneous causes. In: Jennette JC, Olson JL, Schwartz MM, Silva FG, editors. Heptinstall's pathology of the kidney. 5th ed. Philadelphia: Lippincott-Raven; 1998. p.187-257.
25. Glassock RJ. Pathogenesis of the nephrotic syndrome in humans. In: Cameron JS, Glassock RJ, Whelton A, editors. The nephrotic syndrome. Volume 8. New York: Marcel Dekker, Inc; 1988. p. 163-92.
26. Sharma M, Sharma R, McCarthy ET, Savin VJ. "The FSGS factor:" enrichment and in vivo effect of activity from focal segmental glomerulosclerosis plasma. J Am Soc Nephrol 1999;10:552-61.
27. Kriz W. Gretz N, Lemley KV. Progression of glomerular diseases: is the podocyte the culprit? Kidney Int 1998;54:687-97.
28. Korbet SM. Primary focal segmental glomerulosclerosis. J Am Soc Nephrol 1998;9:1333-40.
29. Kohaut EC, Tejani A. The 1994 annual report of the North American Pediatric Renal Transplant Cooperative Study. Pediatr Nephrol 1996;10:422-34.
30. Kim JY, Kim MY, Lee HS. Glomerular growth in childhood focal segmental glomerulosclerosis. Pediatr Nephrol 1998; 12:108-12.
31. Vehaskari VM. Treatment practices of FSGS among North American pediatric nephrologists. Pediatr Nephrol 1999; 13:301-3.
32. Brater DC. Diuretic therapy. N Engl J Med 1998;339:387-95.
33. Eades SK, Christensen ML. The clinical pharmacology of loop diuretics in the pediatric patient. Pediatr Nephrol 1998; 12:603-16.
34. Fliser D, Zurbrüggen I, Mutschler E, Bischoff I, Nussberger J, Franek E, et al. Coadministration of albumin and furosemide in patients with the nephrotic syndrome. Kidney Int 1999;55:629-34.
35. Wells TG. The pharmacology and therapeutics of diuretics in the pediatric patient. Pediatr Clin North Am 1990;37:463-504.
36. Lilova MI, Velkovski IG, Topalov IB. Thromboembolic complications in children with nephrotic syndrome in Bulgaria (1974-1996). Pediatr Nephrol 2000;15:74-8.
37. Arbeitsgemeinschaft für Pädiatrische Nephrologie. Alternate-day versus intermittent prednisone in frequently relapsing nephrotic syndrome. Lancet 1979;I:401-3.
38. Arbeitsgemeinschaft für Pädiatrische Nephrologie. Short versus standard prednisone therapy for initial treatment of idiopathic nephrotic syndrome in children. Lancet 1988;I:380-3.
39. Brodehl J, Krohn HP, Enrich JHH. The treatment of minimal change nephrotic syndrome (lipoidnephrosis): cooperative studies of the Arbeitsgemeinschaft für Pädiatrische Nephrologie (APN). Klin Pädiat 1982;194:162-5.
40. Brodehl J. The treatment of minimal change nephrotic syndrome: lessons learned from multicentre co-operative studies. Eur J Pediatr 1991;150:380-7.
41. Ehrich JHH, Brodehl J, Arbeitsgemeinschaft für Pädiatrische Nephrologie. Long versus standard prednisone therapy for initial treatment of idiopathic nephrotic syndrome in children. Eur J Pediatr 1993;152:357-61.
42. Bagga A, Hari P, Srivastava RN. Prolonged versus standard prednisolone therapy for initial episode of nephrotic syndrome. Pediatr Nephrol 1999;13:824-7.
43. Hudson EM, Knight JF, Willis NS, Craig JC. Corticosteroid therapy in nephrotic syndrome: a meta-analysis of randomised controlled trials. Arch Dis Child 2000;83:45-51.
44. Pei Y, Cattran D, Delmore T, Katz A, Lang A, Rance P. Evidence suggesting under-treatment in adults with idiopathic focal segmental glomerulosclerosis. Am J Med 1987;82:938-44.
45. The International Study of Kidney Disease in Children. Prospective, controlled trial of cyclophosphamide therapy in children with the nephrotic syndrome. Lancet 1974;II:423-7.
46. Tarshish P, Tobin JN, Bernstein J, Edelmann CM. Cyclophosphamide does not benefit patients with focal segmental glomerulosclerosis: a report of the International Study of Kidney Disease in Children. Pediatr Nephrol 1996;10:590-3.
47. Geary DF, Farine M, Thorner P, Baumal R. Response to cyclophosphamide in steroid-resistant focal segmental glomerulosclerosis: a reappraisal. Clin Nephrol 1984;22:109-13.
48. Jones DP, Stapleton FB, Roy S, Wyatt RJ. Beneficial effect of second courses of cytotoxic therapy in children with minimal change nephrotic syndrome. Pediatr Nephrol 1988;2:291-5.
49. Elhence R, Gulati S, Kher V, Gupta A, Sharma RK. Intravenous pulse cyclophosphamide - a new regimen for steroid-resistant minimal change nephrotic syndrome. Pediatr Nephrol 1994;8:1-3.
50. Rennert WP, Kala UK, Jacobs D, Goetsch S, Verhaart S. Pulse cyclophosphamide for steroid-resistant focal segmental glomerulosclerosis. Pediatr Nephrol 1999;13:113-6.
51. Elzouki AY, Jaiswal OP. Evaluation of chlorambucil therapy in steroid-dependent and cyclophosphamide-resistant children with nephrosis. Pediatr Nephrol 1990;4:459-62.
52. Mendoza SA, Reznik VM, Griswold WR, Krensky AM, Yorgin PD, Tune BM. Treatment of steroid-resistant focal segmental glomerulosclerosis with pulse methylprednisolone and alkylating agents. Pediatr Nephrol 1990;4:303-7.
53. Mendoza SA, Tune BM. Treatment of childhood nephrotic syndrome. J Am Soc Nephrol 1992;3:889-94.
54. Tune BM, Kirpekar R, Sibley RK, Reznik VM, Griswold WR, Mendoza SA. Intravenous methylprednisolone and oral alkylating agent therapy of prednisone-resistant pediatric focal segmental glomerulosclerosis: a long-term follow-up. Clin Nephrol 1995;43:84-8.
55. Tune BM, Lieberman E, Mendoza SA. Steroid-resistant nephrotic focal segmental glomerulosclerosis: a treatable disease. Pediatr Nephrol 1996;10:772-8.
56. Tune BM, Mendoza SA. Treatment of the idiopathic nephrotic syndrome: regimens and outcomes in children and adults. J Am Soc Nephrol 1997;8:824-32.
57. Waldo FB, Benfield MR, Kohaut EC. Methylprednisolone treatment of patients with steroid-resistant nephrotic syndrome. Pediatr Nephrol 1992;6:503-5.
58. Sa GA, Luis JP, Mendonca E, Almeida M, Rosa FC. Treatment of childhood steroid-resistant nephrotic syndrome with pulse methylprednisolone and cyclophosphamide [letter]. Pediatr Nephrol 1996;10:250.
59. Waldo FB, Benfield MR, Kohaut EC. Therapy of focal and segmental glomerulosclerosis with methylprednisolone, cyclosporine A, and prednisone. Pediatr Nephrol 1998; 12:397-400.
60. Aviles DH, Irwin KC, Dublin LS, Vehaskari VM. Aggressive treatment of severe idiopathic focal segmental glomerulosclerosis. Pediatr Nephrol 1999;13:298-300.
61. Yorgin PD, Krasher J, Al-Uzri AY. Pulse methylprednisolone treatment of idiopathic steroid-resistant nephrotic syndrome. Pediatr Nephrol 2001;16:245-50.
62. Adhikari M, Bhimma R, Coovadia HM. Intensive pulse therapies for focal glomerulosclerosis in South African children. Pediatr Nephrol 1997;11:423-8.
63. Borel JF. Mechanism of action of cyclosporine A and rationale for use in nephrotic syndrome. Clin Nephrol 1991;35: S23-S30.
64. Melocoton TL, Kamil ES, Cohen AH, Fine RN. Long-term cyclosporine a treatment of steroid-resistant and steroid-dependent nephrotic syndrome. Am J Kid Disease 1991;18: 583-8.
65. Niaudet P, French Society of Pediatric Nephrology. Steroid-resistant idiopathic nephrotic syndrome and cyclosporin [letter]. Nephron 1991;57:481.
66. Niaudet P, French Society of Pediatric Nephrology. Treatment of childhood steroid-resistant idiopathic nephrosis with a combination of cyclosporine and prednisone. J Pediatr 1994;25:981-986.
67. Hymes LC. Steroid-resistant, cyclosporine-responsive, relapsing nephrotic syndrome. Pediatr Nephrol 1995;9:137-9.
68. Ingulli E, Singh A, Baqi N, Ahmad H, Moazami S, Tejani A. Aggressive, long-term cyclosporine therapy for steroid-resistant focal segmental glomerulosclerosis. J Am Soc Nephrol 1995;5:1820-5.
69. Gregory MJ, Smoyer WE, Sedman A, Kershaw DB, Valentini RP, Johnson K, et al. Long-term cyclosporine therapy for pediatric nephrotic syndrome: a clinical and histologic analysis. J AM Soc Nephrol 1996;7:543-9.
70. Garcia C, Michelon T, Barros V, Mota D, Uhlmann A, Randon R, et al. Cyclosporine in the treatment of steroid-dependent and steroid-resistant idiopathic nephrotic syndrome in children. Transplant Proc 1998;30:4156-7.
71. Hino S, Takemura T, Okada M, Murakami K, Yagi K, Fukushima K, et al. Follow-up of children with nephrotic syndrome treated with a long-term moderate dose of cyclosporine. Am J Kidney Dis 1998;31:932-39.
72. Singh A, Tejani C, Tejani A. One-center experience with cyclosporine in refractory nephrotic syndrome in children. Pediatr Nephrol 1999;13:26-32.
73. Seikaly MG, Prashner H, Nolde-Hurlbert B, Browne R. Long-term clinical and pathological effects of cyclosporine in children with nephrosis. Pediatr Nephrol 2000;14:214-7.
74. Lieberman KV, Tejani A. A randomized double-blind placebo-controlled trial of cyclosporine in steroid-resistant idiopathic focal segmental glomerulosclerosis. J Am Soc Nephrol 1996;7:56-63.
75. Ponticelli C, Rizzoni G, Edefonti A, Altieri P, Rivolta E, Rinaldi S, et al. A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome. Kidney Int 1993; 43:1377-84.
76. Niaudet P, Fuchshuber A, Gagnadoux MF, Habib R, Broyer M. Cyclosporine in the therapy of steroid-resistant idiopathic nephrotic syndrome. Kidney Int 1997;58:S85-90.
77. Milliner DS, Morgenstern BZ. Angiotensin converting enzyme inhibitors for reduction of proteinuria in children with steroid-resistant nephrotic syndrome. Pediatr Nephrol 1991;5:587-90.
78. Trachtman H, Gauthier B. Effect of angiotensin-converting enzyme inhibitor therapy on proteinuria in children with renal disease. J Pediatr 1988;112:295-8.
79. Delucchi A, Acno F, Rodriguez E, Wolff E, Gonzalez X, Cumsille MA. Enalapril and prednisone in children with nephrotic-range proteinuria. Pediatr Nephrol 2000;14:1088-91.
80. Lama G, Luongo I, Piscitelli A, Salsano ME. Enalapril: antiproteinuric effect in children with nephrotic syndrome. Clin Nephrol 2000;53:432-6.
81. Sanjad SA, Al-Abbad A, Al-Shorafa S. Management of hyperlipidemia in children with refractory nephrotic syndrome: the effect of statin therapy. J Pediatr 1997;130:470-4.
82. Muso E, Mune M, Fujii Y, Imai E, Ueda N, Hatta K, et al. Low density lipoprotein apheresis therapy for steroid-resistant nephrotic syndrome. Kidney Int 1999;56:S122-5.
83. Querfeld U. Should hyperlipidemia in children with the nephrotic syndrome be treated? Pediatr Nephrol 1999;13:77-84.
84. Briggs WA, Choi MJ, Scheel PJ. Successful mycophenolate mofetil treatment of glomerular disease. Am J Kidney Dis 1998;31:213-7.
85. Ishikawa H. Mizoribine and mycophenolate mofetil. Curr Med Chem 1999;6:575-97.
86. Miller G, Zimmerman R, Radhakrishnan J, Appel G. Use of mycophenolate mofetil in resistant membranous nephropathy. Am J Kidney Dis 2000;36:250-6.
87. Yoshioka K, Ohashi Y, Sakai T, Ito H, Yoshikawa N, Nakamura H, et al. A multicenter trial of mizoribine compared with placebo in children with frequently relapsing nephrotic syndrome. Kidney Int 2000;58:317-24.
88. Al-Lehbi AM, Al-Mutairi MA, Al-Meshari KA, Alfurayh OI. Mycophenolate mofetil (MMF) in steroid resistant focal segmental glomerulosclerosis (FSGS) (cyclosporine dependent or resistant) (Abstract A0483). J Am Soc Nephrol 1999;10:94A
89. Radhakrishnan J, Wang MM, Matalon A, Cattran DC, Appel GB. Mycophenolate mofetil (MMF) treatment of idiopathic focal segmental glomerular sclerosis (FSGS) (Abstract A0584). J Am Soc Nephrol 1999;10:114A.
90. Savin VJ, Sharma R, Sharma M, McCarthy ET, Swan SK, Ellis E, et al. Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmentai glomerulosclerosis. N Engl J Med 1996;334:878-83.
91. Franke D, Zimmering M, Wolfish N, Ehrich JHH, Filler G. Treatment of FSGS with plasma exchange and immunoadsorption. Pediatr Nephrol 2000;14:965-9.
92. Tahzib M, Frank R, Gauthier B, Valderrama E, Trachtman H. Vitamin E treatment of focal segmental glomerulosclerosis: results of an open-label study. Pediatr Nephrol 1999;13:649-52.
93. McCauley J, Shapiro R, Ellis D, Igdal H, Tzakis A, Starzl TE. Pilot trial of FK 506 in the management of steroid-resistant nephrotic syndrome. Nephrol Dial Transplant 1993; 8:1286-90.
94. Schweda F, Liebl R, Riegger AJ, Kramer BK. Tacrolimus treatment for steroid- and cyclosporin-resistant minimal-change nephrotic syndrome. Nephrol Dial Transplant 1997;12:2433-5.
95. McCauley J, Shapiro R, Scantlebury V, Gilboa N, Jordan M, Jensen C, et al. FK 506 in the management of transplant-related nephrotic syndrome and steroid-resistant nephrotic syndrome. Transplant Proc 1991;23:3354-6.
96. Abramowicz M, Barnett HL, Edelmann CM, Greifer I, Kobayashi O, Arneil GC, et al. Controlled trial of azathioprine in children with nephrotic syndrome: a report for the International Study of Kidney Disease in Children. Lancet 1970;1:959-61.
97. McIntosh RM, Griswold W, Smith FG, Kaufman DB, Urizar R, Vernier RL. Azathioprine in glomerulonephritis: a longterm study. Lancet 1972;I:1085-9.
98. Cade R, Mars D, Privette M, Thompson R, Croker B, Peterson J, et al. Effect of long-term azathioprine administration in adults with minimal-change glomerulonephritis and nephrotic syndrome resistant to corticosteroids. Arch Intern Med 1986;146:737-41.
99. Low CL, McGoldrick MD, Bailie GR. Successful management of steroid-resistant nephrotic syndrome using ibuprofen. Nephron 1997;47:60-2.
100. Velosa JA, Torres VE. Benefits and risks of nonsteroidal anti-inflammatory drugs in steroid-resistant nephrotic syndrome. Am J Kidney Dis 1986;8:345-50.
101. Kleinknecht C, Broyer M, Gubler MC, Palcoux JB. Irreversible renal failure after indomethacin in steroid-resistant nephrosis [letter]. N Engl J Med 1980;302:691.
102. Goonasekera CDA, Koziell AB, Hulton SA, Dillon MJ. Vincristine and focal segmental sclerosis: do we need a multicentre trial? Pediatr Nephrol 1998;12:284-9.
103. Almeida MP, Almeida HA, Rosa FC. Vincristine in steroid-resistant nephrotic syndrome. Pediatr Nephrol 1994;8:79-80.
104. Shearn MA. Mercaptopurine in the treatment of steroid-resistant nephrotic syndrome. N Engl J Med 1965;273:943-7.
105. Pruna A, Metivier F, Akposso K, Saltiel C, Bedrossian J, Idatte JM, et al. Pefloxacin as first-line treatment in nephrotic syndrome. Lancet 1992;340:728-9.
106. Aigrain EJ, Brun P, Bennasr S, Loirat C. Side-effects of pefloxacin in idiopathic nephrotic syndrome. Lancet 1993;342:438-9.
107. Geffriaud-Ricouard C, Jungers P, Chauveau D, Grunfeld JP. Inefficacy and toxicity of pefloxacin in focal and segmental glomerulosclerosis with steroid-resistant nephrotic syndrome [letter]. Lancet 1993;341:1475.
108. Ginsburg C, Toledano D, Deray G, Vlassopoulos D, Baumelou A, Jacobs C. Pefloxacin as first-line treatment in nephrotic syndrome [letter]. Nephrol Dial Transplant 1994;9:335.
109. Korzets Z, Pomeranz A, Golan E, Bernheim J. Pefloxacin in adriamycin induced nephrotic syndrome in the rat. Nephrol Dial Transplant 1997;12:286-8.
110. Berthoux F, Alamartine E, Lambert C. More about pefloxacin and nephrotic syndrome. Nephrol Dial Transplant 1994; 9:1838-9.
111. British Association for Paediatric Nephrology. Levamisole for corticosteroid-dependent nephrotic syndrome in childhood. Lancet 1991;337:1555-7.
112. Mancini ML, Rinaldi S, Rizzoni G. Treatment of partially corticosteroid-sensitive nephrotic syndrome [letter], Pediatr Nephrol 1994;8:788.
113. Ginevri F, Trivelli A, Ciardi MR, Ghiggeri GM, Parfumo F, Gusmano R. Protracted levamisole in children with frequent-relapse nephrotic syndrome [letter]. Pediatr Nephrol 1996; 10:550.
114. Bagga A, Sharma A, Srivastava RN. Levamisole therapy in corticosteroid-dependent nephrotic syndrome. Pediatr Nephrol 1997;11:415-7.
115. Tenbrock K, Muller-Berghaus J, Fuchshuber A, Michalk D, Querfeld U. Levamisole treatment in steroid-sensitive and steroid-resistant nephrotic syndrome. Pediatr Nephrol 1998; 12:459-62.
116. Srivastava RN. Levamisole therapy in nephrotic syndrome [letter]. Pediatr Nephrol 1999;13:636.
117. Cattran DC, Rao P. Long-term outcome in children and adults with classic focal segmental glomerulosclerosis. Am J Kidney Dis 1998;32:72-9.
118. Korbet SM, Schwartz MM, Lewis EJ. Primary focal segmentai glomerulosclerosis: clinical course and response to therapy. Am J Kidney Dis 1994;23:773-83.
119. Ingulli E, Tejani A. Racial differences in the incidence and renal outcome of idiopathic focal segmental glomerulosclerosis in children. Pediatr Nephrol 1991;5:393-7.
120. Soroff JM, Hawkins EP, Brewer ED, Boydstun II, Kale AS, Powell DR. Age and ethnicity affect the risk and outcome of focal segmental glomerulosclerosis. Pediatr Nephrol 1998; 12:764-8.
121. Vande Walle JGJ, Donckerwolcke RA, Koomans HA. Pathophysiology of edema formation in children with nephrotic syndrome not due to minimal change disease. J Am Soc Nephrol 1999;10:323-31.
122. Vande Walle JGJ, Donckerwolcke RA. Pathogenesis of edema formation in the nephrotic syndrome. Pediatr Nephrol 2001;16:283-93.
123. Barness LA, Moll GH, Janeway CA. Nephrotic syndrome -I: natural history of the disease. 1950;5:486-503.
124. American Academy of Pediatrics. Active and passive immunization. In: Pickering LK, editor. 2000 Red Book: report of the Committee on Infectious Diseases. 25th ed. Elk Grove (IL): American Academy of Pediatrics; 2000. p. 1-81.
125. Andrew M, Brooker LA. Hemostatic complications in renal disorders of the young. Pediatr Nephrol 1996;10:88-99.
126. Hoyer PF, Gonda S, Barthels M, Krohn HP, Brodehl J. Thromboembolic complications in children with nephrotic syndrome. Acta Paediatr Scand 1986;75:804-10.
127. Niaudet P. Steroid-resistant idiopathic nephrotic syndrome. In: Barratt TM, Avner ED, Harmon WE, editors. Pediatric nephrology. 4th ed. Baltimore: Lippincott Williams & Wilkins; 1998. p. 749-63.
128. Vaziri ND. Erythropoietin and transferrin metabolism in nephrotic syndrome. Am J Kidney Dis 2001;38:1-8.
129. Schärer K, Essigmann HC, Schaefer F. Body growth of children with steroid-resistant nephrotic syndrome. Pediatr Nephrol 1999;13:828-34.
130. O'Reagan S, Murphy FG, Robitailee P, Russo P, Klassen J. Decreased hospitalization and increased height velocity in focal segmental glomerulosclerosis responsive to ciclosporin A. Child Nephrol Urol 1991;11:185-98.
131. Kestilä M, Lennkkeri U, Männikkö M, Plamerdin J, McCready P, Putaala H, et al. Positionally cloned gene for a novel glomerular protein-nephrin-is mutated in congenital nephrotic syndrome. Mol Cell 1998;1:575-82.
132. Beltcheva O, Martin P, Lenkkeri U, Tryggvason K. Mutation spectrum in the nephrin gene (NPHS1) in congenital nephrotic syndrome. Hum Mutat 2001;17:368-73.
133. Ruotsalainen V, Patrakka J, Tissari P, Reponen P, Hess M, Kestilä M, et al. Role of nephrin in cell junction formation in human nephrogenesis. Am J Pathol 2000;157:1905-16.
134. Patrakka J, Ruotsalainen V, Ketola I, Holmberg C, Heikinheimo M, Tryggvason K, et al. Expression of nephrin in pediatric kidney diseases. J Am Soc Nephrol 2001;12:289-96.
135. Benigni A, Tomasoni S, Gagliardini E, Zoja C, Grunkemeyer JA, Kalluria R, et al. Blocking angiotensin II synthesis/activity preserves glomerular nephrin in rats with severe nephrosis. J Am Soc Nephrol 2001;12:941-8.
136. Doublier S, Ruotsalainen V, Salvidio G, Lupia E, Biancone L, Conaldi PG, et al. Nephrin redistribution on podocytes is a potential mechanism for proteinuria in patients with primary acquired nephrotic syndrome. Am J Pathol 2001; 158:1723-31.
137. Putaala H, Soininen R, Kilpeläinen P, Wartiovaara J, Tryggvason K. The murine nephrin gene is specifically expressed in kidney, brain and pancreas: inactivation of the gene leads to massive proteinuria and neonatal death. Hum MoL Genet 2001;10:1-8.
138. Boute N, Gribouval O, Roselli S, Benessy F, Lee H, Fuchshuber A, et al. NPHS2, encoding the glomerular protein podocin, is mutated in autosomal recessive steroid-resistant nephrotic syndrome. Nature Genet 2000;24:349-54.
139. Kaplan J, Pollak MR. Familial focal segmental glomerulosclerosis. Curr Opin Nephrol Hypertens 2001;10:183-7.
140. Winn MP, Conlon PJ, Lynn KL, Howell DN, Slotterbeck BD, Smith AH, et al. Linkage of a gene causing familial focal segmental glomerulosclerosis to chromosome 11 and further evidence of genetic heterogeneity. Genomics 1999;58:113-20.
141. Koziell AB, Grundy R, Barratt TM, Scambler P. Evidence for the genetic heterogeneity of nephropathic phenotypes associated with Denys-Drash and Frasier syndromes. Am J Hum Genet 1999;64:1778-81.
142. McTaggart SJ, Algar E, Chow CW, Powell HR, Jones CL. Clinical spectrum of Denys-Drash and Frasier syndrome. Pediatr Nephrol 2001;16:335-9.
143. Mrowka C, Schedl A. Wilms' tumor suppressor gene WT1; from structure to renal pathophysiologic features. J Am Soc Nephrol 2000;11:S-106-S-115.
144. Little M, Wells C. A clinical overview of WT1 gene mutations. Hum Mutat 1997;9:209-25.
145. Koziell A, Grundy R. Frasier and Denys-Drash syndromes: different disorders or part of a spectrum? Arch Dis Child 1999;81:365-9.
146. Takata A, Kikuchi H, Fukuzawa R, Ito S, Honda M, Hata JI. Constitutional WT1 mutations correlate with clinical features in children with progressive nephropathy. J Med Genet 2000;37:698-701.
147. Hirose M. The role of Wilms' tumor genes. J Med Invest 1999;46:130-40.
148. Denamur E, Bocquet N, Baudouin V, Da Silva F, Veitia R, Peuchmaur M, et al. WT1 splice-site mutations are rarely associated with primary steroid-resistant focal and segmental glomerulosclerosis. Kidney Int 2000;57:1868-72.
149. Striegel JE, Sibley RK, Fryd DS, Mauer SM. Recurrence of focal segmental sclerosis in children following renal transplantation. Kidney Int 1986;30:S44-S50.
150. Senggutuvan P, Cameron JS, Hartley RB, Rigden S, Chantler C, Haycock G, et al. Recurrence of focal segmental glomerulosclerosis in transplanted kidneys: analysis of incidence and risk factors in 59 allografts. Pediatr Nephrol 1990;4:21-8.
151. Ingulli E, Tejani A. Incidence, treatment, and outcome of recurrent focal segmental glomerulosclerosis posttransplantation in 42 allografts in children - a single-center experience. Transplantation 1991;51:401-5.
152. Tejani A, Stablein DH. Recurrence of focal segmental glomerulosclerosis posttransplantation: a special report of the North American Pediatric Renal Transplant Cooperative Study. J Am Soc Nephrol 1992;2:S258-S263.
153. Wühl E, Fydryk J, Wiesel M, Mehls O, Scaefer F, Schärer K. Impact of recurrent nephrotic syndrome after renal transplantation in young patients. Pediatr Nephrol 1998;12:529-33.
154. Dall'Amico R, Ghiggeri GM, Carraro M, Artero M, Ghio L, Zamorani E, et al. Prediction and treatment of recurrent focal segmental glomerulosclerosis after renal transplantation in children. Am J Kidney Dis 1999;34:1048-55.
155. Butani L, Polinsky MS, Kaiser BA, Baluarte HJ. Predictive value of race in post-transplantation recurrence of focal segmental glomerulosclerosis in children. Nephrol Dial Transplant 1999;14:166-8.
156. Kim SJ, Ha J, Jung IM, Ahn MS, Kim M, Lee HS, et al. Recurrent focal segmental glomerulosclerosis following renal transplantation in Korean pediatric patients. Pediatr Transplantation 2001;5:105-11.
157. Carl S, Wiesel M, Wühl E, Mehls O, Schaefer F, Staehler G. Outcome of children and adolescents with recurrent nephrotic syndrome and focal segmental glomerulosclerosis after renal transplantation. Transplant Proc 1997;29:2795-6.
158. Kim EM, Striegel J, Kim Y, Matas AJ, Najarian JS, Mauer SM. Recurrence of steroid-resistant nephrotic syndrome in kidney transplants is associated with increased acute renal failure and acute rejection. Kidney Int 1994;45:1440-5.
159. Felldin M, Nordén G, Svalander C, Nyberg G. Focal segmental glomerulosclerosis in a kidney transplant population: hereditary and sporadic forms. Transpl Int 1998;11:16-21.
160. Cochat P, Kassir A, Colon S, Glastre C, Tourniaire B, Parachoux B, et al. Recurrent nephrotic syndrome after transplantation: early treatment with plasmapheresis and cyclophosphamide. Pediatr Nephrol 1993;7:50-4.
161. Saleem MA, Ramanan AV, Rees L. Recurrent focal segmentai glomerulosclerosis in grafts treated with plasma exchange and increased immunosuppression. Pediatr Nephrol 2000;14: 361-4.
162. Greenstein SM, Delrio M, Ong E, Feuerstein D, Schechner R, Kim D, et al. Plasmapheresis treatment for recurrent focal sclerosis in pediatric allografts. Pediatr Nephrol 2000;14: 1061-5.
163. Lane PH, Schnaper HW, Vernier RL, Bunchman TE. Steroid-dependent nephrotic syndrome following renal transplantation for congenital nephrotic syndrome. Pediatr Nephrol 1991;5:300-3.
164. Laine J, Jalanko H, Holthöfer H, Krogerus L, Rapola J, von Willebrand E, et al. Post-transplantation nephrosis in congenital nephrotic syndrome of the Finnish type. Kidney Int 1993;44:867-74.
165. Kim MS, Stablein D, Harmon WE. Renal transplantation in children with congenital nephrotic syndrome: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Pediatr Transplantation 1998;2:305-8.